Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00454
|
|||||
| Drug Name |
Sunitinib
|
|||||
| Synonyms |
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; KS-5022; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; PDGF TK antagonist; SU-11248J; SU-12662; SU11248; Su-011248; Sunitanib; Sunitinib (INN); Sunitinib (Pan-TK inhibitor); Sunitinib (free base); Sunitinibum; Sutent (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Advanced renal cell carcinoma [ICD11: 2C90] | Approved | [1] | |||
| Imatinib-resistant gastrointestinal stromal tumor [ICD11: 2B5B] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H27FN4O2
|
|||||
| Canonical SMILES |
CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
|
|||||
| InChI |
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
|
|||||
| InChIKey |
WINHZLLDWRZWRT-ATVHPVEESA-N
|
|||||
| CAS Number |
CAS 557795-19-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 398.5 | Topological Polar Surface Area | 77.2 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103175813
, 104178853
, 104223163
, 11061329
, 113911638
, 118049563
, 118855335
, 124893175
, 124893176
, 126663102
, 134222706
, 134337335
, 134339174
, 135236614
, 136367772
, 137001819
, 137255559
, 137255561
, 140170598
, 14720359
, 14830382
, 152047612
, 160964598
, 162012027
, 162184461
, 163371066
, 163395369
, 164045165
, 164825281
, 164825282
, 172085035
, 172091423
, 172919594
, 176484660
, 176485072
, 26675759
, 26758053
, 39301727
, 46507140
, 50070562
, 50071184
, 50100120
, 57361294
, 8034462
, 80856906
, 85171053
, 91148451
, 93581003
, 96025237
, 99443888
|
|||||
| ChEBI ID |
ChEBI:38940
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| RALBP1 | Transporter Info | RalBP1-associated Eps domain-containing protein 2 | Substrate | [5] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | RALBP1 | Transporter Info | Km = 7.2 microM | Human kidney cancer cells (Caki-2)-RALBP1 | [5] | |
| References | ||||||
| 1 | Sunitinib malate was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82. | |||||
| 3 | Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. | |||||
| 4 | Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. | |||||
| 5 | Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.